Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05150587 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
A Phase 2 study of Papulopustular Rosacea, sponsored by Alfasigma S.p.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
- 20
- Study locations
NCT05150587 is a Phase 2 study of Papulopustular Rosacea that has completed, run by Alfasigma S.p.A.. The registered enrollment target is 216 participants, below the 260-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05150587, a Phase 2 study of Papulopustular Rosacea, has completed, sponsored by Alfasigma S.p.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
- 20
- Study locations
Study Summary
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes. Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral antibiotic drug may be beneficial in patients with rosacea, particularly in those with papulopustular phenotype and positivity to Lactulose Breath Test (L-BT). The objective of this study is twofold: 1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults with moderate-to-severe papulopustular rosacea. 2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rifaximin
Study Locations (20)
California
- Long Beach Clinical Trials - Long Beach
- Metropolis Dermatology - Los Angeles
- LA Universal Research Center - Los Angeles
- Cosmetic Laser Dermatology - San Diego
- UCSD - San Diego
- University Clinical Trials, Inc. - San Diego
Florida
- Skin Care Research - Boca Raton
- MOORE Clinical Research,Inc. - Brandon
- Sweet Hope Research Specialty, Inc. - Hialeah
- Savin Medical Group - Miami Lakes
- Leavitt Medical Associates of Florida - Ormond Beach
Louisiana
- Delricht Research Baton Rouge LA - Baton Rouge
- Delricht Research Covington LA - Covington
- DelRicht Research Houma Louisiana - Houma
Kentucky
- Skin Science PLLC - Louisville
- DS Research - Louisville
Arizona
- Dermatology Research Ventures - Yuma
Arkansas
- Johnson Dermatology - Fort Smith
Georgia
- DelRicht Research - Marietta
Indiana
- DS Research - Clarksville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-10-05 |
| Est. Completion | 2022-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05150587
The ClinicalTrials.gov registry entry for NCT05150587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (17% lower). The listed sponsor is Alfasigma S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papulopustular Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05150587 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05150587 about?
NCT05150587 is a clinical study titled "Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea". Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes. Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral antibiotic drug may be beneficial in patients with rosacea, particu...
What is the current status of trial NCT05150587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2021-10-05. Estimated completion is 2022-10-20.
What conditions does trial NCT05150587 study?
This clinical trial studies the following conditions: Papulopustular Rosacea.
What interventions are being tested in trial NCT05150587?
The interventions under investigation include: Placebo (DRUG), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT05150587?
This trial is sponsored by Alfasigma S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05150587 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
A Twelve Week Safety and Efficacy Study in Rosacea
COMPLETED · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
-
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.